No abstract available.
Humans ; Pyroglyphidae* ; Rhinitis* ; Sublingual Immunotherapy*

China ; Humans ; Sublingual Immunotherapy ; adverse effects ; methods

Humans ; Rhinitis, Allergic ; drug therapy ; Sublingual Immunotherapy

Food allergy is common and sometimes life threatening for Korean children. The current standard treatment of allergen avoidance and self-injectable epinephrine does not change the natural course of food allergy. Recently, oral, sublingual, and epicutaneous immunotherapies have been studied for their effectiveness against food allergy. While various rates of desensitization (36% to 100%) and tolerance (28% to 75%) have been induced by immunotherapies for food allergy, no single established protocol has been shown to be both effective and safe. In some studies, immunologic changes after immunotherapy for food allergy have been revealed. Adverse reactions to these immunotherapies have usually been localized, but severe systemic reactions have been observed in some cases. Although immunotherapy cannot be recommended for routine practice yet, results from recent studies demonstrate that immunotherapies are promising for the treatment of food allergy.
Child ; Epinephrine ; Food Hypersensitivity* ; Humans ; Immunotherapy* ; Sublingual Immunotherapy

BACKGROUND AND OBJECTIVES: Comparative clinical studies of sublingual and subcutaneous treatments have yielded heterogeneous results. In this study, we compared clinical outcomes in patients allergic to house dust mites (HDMs) that received at least 1 year of subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT). SUBJECTS AND METHOD: The present study included 120 patients with HDM allergic rhinitis, 54 patients in the SCIT group and 66 patients in the SLIT group. Each patient was asked to answer a set of questionnaire before starting immunotherapy. The questionnaires included the rhinoconjunctivitis quality of life questionnaire (RQLQ) and a patient satisfaction questionnaire. The patients were asked to answer the questions after undergoing at least 1 year of immunotherapy. RESULTS: RQLQ scores collected after immunotherapy in both SCIT and SLIT groups were decreased significantly. However, the SCIT group had a significantly higher decrease in RQLQ scores for non-nose/eye symptoms than the SLIT group (p-value=0.015). There were no differences in other satisfaction scores between the two groups. SCIT improved clinical symptoms faster than SLIT did within 6 months and 1 year (p-value=0.011, p-value=0.045 respectively). CONCLUSION: SCIT is more effective than SLIT in improving non-nose/eye symptoms in patients with allergic rhinitis. SCIT may relieve the symptoms faster than SLIT.
Humans ; Immunotherapy* ; Patient Satisfaction* ; Pyroglyphidae ; Quality of Life ; Rhinitis* ; Sublingual Immunotherapy*

Clinical trials of intralymphatic immunotherapy (ILIT) have been performed to overcome the limitations of long-term therapy and the local or systemic hypersensitivity reactions in conventional allergen-specific immunotherapy, including subcutaneous or sublingual immunotherapy. Additionally, several animal studies of ILIT have been conducted in the form of translational or veterinary research. We conducted a literature review to examine the treatment efficacy and adverse effects of ILIT.
Animals ; Humans ; Hypersensitivity ; Immunotherapy ; Injections, Intralymphatic ; Sublingual Immunotherapy ; Treatment Outcome

To analyze the impact of sublingual immunotherapy(SLIT)on the quality of life in children with allergic rhinitis.Fifty children with allergic rhinitis who have received sublingual immunotherapy were enrolled in this study.Quality of life was evaluated via measurement of VAS score and rhinoconjunctivitis quality of life questionnaire(RQLQ)before and after treatment.Twenty patients after treatment had complete remission,13 cases were partly alleviated and 17 cases had no response.The total effective rate was 66%.The Multi-VAS scores and Uni-VAS scores in each observation time point(at half a year,one year,two years after treatment)had statistically significant difference compared with that of pre-treatment with SLIT(<0.05).According to RQLQ scores,the quality of life,nasal symptoms,conjunctiva symptoms,non-nasal(ocular)symp-toms,behaviors and emotional responses were greatly improved in each time point compared with that of pretreatment(<0.05).Symptomatic treatment scores in each time point after treatment were significantly different and had a positive correlation with the scores of RQLQ(<0.05).SLIT can improve the nasal allergic symptoms,children's life quality and reduce the use of symptomatic treatment medicines.
Administration, Sublingual ; Child ; Humans ; Quality of Life ; Rhinitis, Allergic ; therapy ; Sublingual Immunotherapy ; Treatment Outcome

Asthma is a chronic inflammatory disease of the airway that comprises a variety of etiologies and inflammatory phenotypes. Clinically, there is a wide range of patients with varying severities and responses to individual drugs. The introduction of inhaled corticosteroid therapy has dramatically changed the treatment of asthma. Recent development of new therapies suggests the possibility of another breakthrough. These can be categorized as follows: anti-cytokine therapies that usually target eosinophilic inflammation, sublingual immunotherapy, and bronchial thermoplasty. In this paper, we will review the major articles related to asthma treatment that were published in 2013.
Asthma* ; Cytokines ; Eosinophilia ; Eosinophils ; Humans ; Inflammation ; Phenotype ; Sublingual Immunotherapy

Administration, Sublingual ; Humans ; Immunotherapy ; methods ; Inflammation ; Respiratory Hypersensitivity ; therapy

Objective:To monitor adherence to specific sublingual immunotherapy （SLIT） in patients with seasonal allergic rhinitis（AR）, analyse factors influencing adherence, and provide research support to effectively improve adherence. Methods:Patients with AR who underwent Artemisia pollen SLIT at the Department of Otolaryngology-Head and Neck Surgery, First Hospital of Shanxi Medical University from May 2021 to April 2022 were retrospectively followed up by telephone to investigate the current status of treatment, count the causes of shedding, and extract relevant information from their medical record data for analysis. Results:Of the 112 patients surveyed, 34 discontinued treatment（30.3%）; patients who experienced adverse reactions and SLIT patients who had been on treatment for more than 6 months showed relatively good adherence（P<0.05）. The main reasons for discontinuation in patients who dropped out were: asymptomatic discomfort during the non-pollen phase and therefore discontinuation of treatment or feeling that treatment was ineffective 9 cases（26.5%）, forced discontinuation due to vaccination or pregnancy, or epidemics 6 cases（17.6%）. Conclusion:Long-term adherence of patients to Artemisia pollen SLIT still needs to be brought to the attention of healthcare professionals, especially in the early stages of treatment when good patient education and good channels of trust and communication between doctors and patients need to be established.
Humans ; Sublingual Immunotherapy ; Allergens ; Retrospective Studies ; Rhinitis, Allergic/therapy* ; Artemisia